Jianjun Zou
China Pharmaceutical University(CN)Ministry of Natural Resources(CN)Ministry of Natural Resources(CN)Bioscience Research(US)Qingdao National Laboratory for Marine Science and Technology(CN)First Institute of Oceanography(CN)Hangzhou Red Cross Hospital(CN)Guangzhou Chest Hospital(CN)Nanjing Medical University(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, Acute Ischemic Stroke Management
Most-Cited Works
- → Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma(2021)773 cited
- → Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial(2020)632 cited
- → Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study(2020)575 cited
- → Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial(2020)492 cited
- → Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial(2021)439 cited